CLDN18 and neoplasm: Besides, clinical trials (FAST study) which investigated CLDN18 tumor expression and therapy with anti-CLDN18 demonstrated that Zolbetuximab (IMAB362) in combination with first-line chemotherapy provides a clinically relevant benefit in patients with inoperable or recurrent gastric and gastro-esophageal junction cancer [49,50].